Glabrescione B is primarily researched for its potential in cancer therapy due to its ability to inhibit the Hedgehog signaling pathway, which is often implicated in various cancers. This compound shows promise in targeting and suppressing the growth of cancer cells, particularly in basal cell carcinoma and medulloblastoma. Additionally, it is being explored for its role in developing new therapeutic agents that can selectively disrupt aberrant signaling pathways in tumor cells. Its application extends to biomedical research where it serves as a valuable tool for studying Hedgehog pathway mechanisms and their involvement in oncogenesis.